Meiji Pharmaceutical University (明治薬科大学, Meiji yakka daigaku) is a private university in Kiyose, Tokyo, Japan. The predecessor of the school was founded 1902..
Advanced glycation end-products (AGEs), having multiple structures, are formed at the sites where the carbonyl groups of the reducing sugars bind to the free amino groups of the proteins through the Maillard reaction. The accumulation of AGEs, which are generated when carbonyl compounds produced in the process of glucose metabolism react with proteins, is involved in various carbonyl stress-related diseases. Meanwhile, guanidine compounds, represented by aminoguanidine, have possibilities as a scavenger that inhibits AGE formation by directly reacting with carbonyl compounds. We here focused on existing drugs with a guanidine-like structure and estimated the reactivity of nine drugs, including aminoguanidine, with methylglyoxal (MGO), a glucose metabolite, to assess their potential application to carbonyl stress-induced diseases. Considering the results of the two screening methods, we concentrated on streptomycin, which exhibited stable scavenging activity, and evaluated its inhibitory effect on the MGO-induced AGE formation in proteins in vitro. Furthermore, the effects of streptomycin on carbonyl protein accumulation in the cells and the MGO-induced cytotoxicity were investigated to elucidate the cytoprotective potential against glycation. The results revealed that streptomycin added to the culture medium with MGO suppressed the MGO-induced carbonylation of intracellular proteins and exerted a protective effect by alleviating the toxicity of MGO in a study using human-derived neuroblastoma SH-SY5Y. These findings suggest that the clinically available streptomycin has a potential to be utilized for carbonyl stress-related diseases as a repurposing drug.
PURPOSE:Amikacin (AMK) is a widely used therapeutic drug monitoring (TDM)-recommended treatment for nontuberculous mycobacterial pulmonary disease (NTM-PD). However, its optimal dosage and TDM target remain unclear. In this study, we aimed to clarify the relationship between AMK exposure, ototoxicity, and efficacy. METHODS:Patients with NTM-PD treated with AMK at Fukujuji Hospital were retrospectively included in this study. The correlation between AMK exposure, measured by peak and trough levels and the area under the concentration-time curve (AUC), ototoxicity, and culture conversion was analyzed using the Mann-Whitney U test and Cox regression analysis. A population pharmacokinetic/pharmacodynamic (PPK/PD) model was developed to predict ototoxicity using TDM measurements. RESULTS:A total of 185 patients were enrolled. The median AMK dose and observation period were 500 (interquartile range [IQR], 500-600) mg/day and 45.8 (IQR, 31.3-76.5) months, respectively. Ototoxicity and culture conversion were observed in 39% and 54% of the enrolled patients, respectively, after initiating AMK. The median time to the development of ototoxicity was 69 (IQR; 43-97) days. Neither ototoxicity nor culture conversion was associated with pharmacokinetic parameter of AMK exposure, including its minimum inhibitory concentration. However, the cumulative AUC was significantly higher in patients who developed ototoxicity (P < 0.001) than in those without ototoxicity. The developed PPK/PD model enabled calculation of cumulative AUC from TDM data and prediction of ototoxicity onset. CONCLUSION:Cumulative AMK exposure was associated with ototoxicity, and our findings allow prediction of ototoxicity onset using AMK TDM data.
Phospholipase A2 group VI (PLA2G6, also called iPLA2β) has been implicated in male fertility, neuronal disorders, and metabolic diseases. However, its therapeutic effects on metabolic disorders remain elusive. We investigated the effects of PLA2G6 suppression on glucose and lipid metabolism. Systemic inhibition of PLA2G6 in high-fat diet-fed mice reduced hepatic lipid droplet size without altering the levels of serum triglycerides and fasting blood glucose. Suppression of liver-specific Pla2g6 utilizing the short-hairpin RNA knockdown technique using an adenovirus vector (Ad-shPLA2G6) altered phospholipid and fatty acid metabolites and suppressed hepatic lipid accumulation, serum triglyceride, fasting glucose, and insulin levels. Additionally, Ad-shPLA2G6 treatment downregulated lipid biosynthesis-related genes but upregulated peroxisomal fatty acid oxidation-related genes. These findings indicate that targeting hepatic Pla2g6 modulates phospholipid and fatty acid metabolites and improves glucose and lipid metabolism, suggesting Pla2g6 as a potential therapeutic target in metabolic disorders, including type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
Composite major congenital malformation (MCM) outcomes are commonly used to assess teratogenic effects of prenatal medication exposure, but this approach dilutes effect estimates when the risk is confined to a specific MCM. Tree-based scan statistics address this by screening outcomes using a hierarchical tree, enabling detection of specific risks without predefined hypotheses. To apply this method across ICD-9-CM and ICD-10-CM eras, we developed a unified hierarchical outcomes tree for MCM. We selected ICD-9-CM and ICD-10-CM codes classified as congenital anomalies, removing minor malformations, chromosomal anomalies, and single-gene conditions. A multilevel tree was built based on the Multi-level Clinical Classification Software, General Equivalence Mappings, and expert review. We validated the tree using birth cohorts from MarketScan and Medicaid databases (2011-2013; 2016-2018), assessing the balance of MCM prevalences within 1 year of birth via standardized mean differences (SMDs). The final tree included 1023 codes, organized into 244 clinical MCM groups at the most granular level. We identified 572 107 (2011-2013) and 360 167 infants (2016-2018) in MarketScan and 362 820 and 3 500 589 infants in Medicaid. All SMDs were below 0.1, indicating consistency across coding eras. This hierarchical MCM tree bridges ICD-9-CM and ICD-10-CM, enabling consistent outcome definitions and enhancing the detection of specific teratogenic risks.